Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in Resectable NSCLC
NCT04875585Phase 2Recruiting
- Sponsor
- Medical University of Innsbruck
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in non-small cell lung cancer (NSCLC), sponsored by Medical University of Innsbruck. Started May 2021; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04875585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875585.